Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning

The increasing appreciation of oncogenic driver alterations in non-small cell lung cancer (NSCLC) has resulted in a rapid expansion of therapeutic compounds. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations are the prototypical examples and have driven the par...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Klempner, Samuel J., Raufi, Alexander, Ou, Sai-Hong Ignatius
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2015
Assuntos:
Editorial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4630509/
https://ncbi.nlm.nih.gov/pubmed/26629439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados